Suchergebnisse - "SUBKLEWE MARION"

PubPharm (326)

41

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma : Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

enthalten in: HemaSphere | 2023

von Bücklein, V. | Perez, A. | Rejeski, K. | +24

ErratumIn: Hemasphere. 2023 Oct 31;7(11):e982. - PMID 37920708

42

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

enthalten in: Journal of hematology & oncology | 2023

von Rejeski, K. | Hansen, D. | Bansal, R. | +15

43

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

enthalten in: Journal of hematology & oncology | 2023

von Rejeski, K. | Hansen, D. | Bansal, R. | +15

44

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

enthalten in: Journal of hematology & oncology | 2023

von Rejeski, K. | Hansen, D. | Bansal, R. | +15

45

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumIn: Cancer Immunol Immunother. 2023 May 8;:. - PMID 37154851

46

Correction to : CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumFor: Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. - PMID 37041225

47

Cellular therapy in lymphoma

enthalten in: Hematological oncology | 2023

von Sureda, A. | Lugtenburg, P. | Kersten, M. | +11

48

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

enthalten in: Cancer immunology research | 2023

von Rejeski, K. | Cordas Dos Santos, D. | Parker, N. | +14

CommentIn: Cancer Immunol Res. 2023 Jun 2;11(6):704. - PMID 37264818

49

Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy

enthalten in: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2023

von Fan, J. | Adams, A. | Sieg, N. | +22

50

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy

enthalten in: Blood advances | 2023

von Reimann, H. | Kremer, A. | Blumenberg, V. | +23